- Trials with a EudraCT protocol (16)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
16 result(s) found for: Costovertebral angle tenderness.
Displaying page 1 of 1.
EudraCT Number: 2004-004573-29 | Sponsor Protocol Number: DORI-06 | Start Date*: 2005-01-21 | |||||||||||
Sponsor Name:Peninsula Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Multicenter, Phase 3 Study to Confirm the Safety and Efficacy of Intravenous Doripenem in Complicated Lower Urinary Tract Infection or Pyelonephritis | |||||||||||||
Medical condition: Complicated Lower Urinary Tract Infection or Pyelonephritis MedDRA: Lower urinary tract infection or pyelonephritis (10024981 and/or 10059517) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003671-35 | Sponsor Protocol Number: SPR994-301 | Start Date*: 2019-04-18 | |||||||||||
Sponsor Name:Spero Therapeutics, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-blind, Double-dummy, Multicenter, Prospective Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) ... | |||||||||||||
Medical condition: complicated urinary tract infection or acute pyelonephritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: EE (Completed) LV (Completed) BG (Completed) HU (Completed) PL (Completed) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-023453-11 | Sponsor Protocol Number: CXA-cUTI-10-05 | Start Date*: 2011-08-04 | |||||||||||
Sponsor Name:Cubist Pharmaceuticals, Inc. | |||||||||||||
Full Title: A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PHASE 3 STUDY TO COMPARE THE SAFETY AND EFFICACY OF INTRAVENOUS CXA 201 AND INTRAVENOUS LEVOFLOXACIN IN COMPLICATED URINARY TRACT INFECTION, INCLUDING PYELO... | |||||||||||||
Medical condition: Complicated Urinary Tract Infection, Including Pyelonephritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) ES (Prematurely Ended) SI (Completed) BG (Completed) EE (Prematurely Ended) LV (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-005161-31 | Sponsor Protocol Number: AT-201 | Start Date*: 2017-07-04 | ||||||||||||||||
Sponsor Name:Allecra Therapeutics SAS | ||||||||||||||||||
Full Title: Randomized, Double-Blind, Multi-Center Study of Cefepime/AAI101 in Hospitalized Adults With Complicated Urinary Tract Infections, Including Acute Pyelonephritis | ||||||||||||||||||
Medical condition: Complicated urinary tract infections including acute pyelonephritis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: HU (Completed) PL (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2010-023452-87 | Sponsor Protocol Number: CXA-cUTI-10-04 | Start Date*: 2011-08-11 | |||||||||||
Sponsor Name:Cubist Pharmaceuticals, Inc. | |||||||||||||
Full Title: A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PHASE 3 STUDY TO COMPARE THE SAFETY AND EFFICACY OF INTRAVENOUS CXA 201 AND INTRAVENOUS LEVOFLOXACIN IN COMPLICATED URINARY TRACT INFECTION, INCLUDING PYELO... | |||||||||||||
Medical condition: Complicated Urinary Tract Infection, Including Pyelonephritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) HU (Completed) SK (Completed) LV (Completed) EE (Completed) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-003975-80 | Sponsor Protocol Number: SHORTCUT | Start Date*: 2018-03-07 |
Sponsor Name:Academic Medical Center | ||
Full Title: Shorter treatment of catheter related urinary tract infections | ||
Medical condition: Catheter related urinary tract infection (CAUTI) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2018-000037-13 | Sponsor Protocol Number: PTK0796-AP-17202 | Start Date*: 2018-09-04 | |||||||||||
Sponsor Name:Paratek Pharma, LLC, a wholly-owned subsidiary of Paratek Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Randomized, Double-Blinded, Adaptive Phase 2 Study to Evaluate the Safety and Efficacy of IV or IV/PO Omadacycline and IV/PO Levofloxacin in the Treatment of Adults with Acute Pyelonephritis | |||||||||||||
Medical condition: Acute Pyelonephritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: LV (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-001451-13 | Sponsor Protocol Number: VNRX-5133-201 | Start Date*: 2019-07-02 | |||||||||||
Sponsor Name:Venatorx Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-blind, Active-controlled Noninferiority Study Evaluating the Efficacy, Safety, and Tolerability of Cefepime/VNRX-5133 in Adults with Complicated Urinary Tract Infecti... | |||||||||||||
Medical condition: Complicated Urinary Tract Infections, Including Acute Pyelonephritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LV (Completed) CZ (Completed) HU (Completed) BG (Completed) HR (Completed) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-022487-12 | Sponsor Protocol Number: CXL-MD-02 | Start Date*: 2011-02-25 | |||||||||||
Sponsor Name:Cerexa, Inc | |||||||||||||
Full Title: A Phase 2, Multicenter, Randomized, Double-blind, Comparative Study to Evaluate the Efficacy and Safety of Intravenous Coadministered Ceftaroline fosamil and NXL104 Versus Intravenous Doripenem in ... | |||||||||||||
Medical condition: Complicated Urinary Tract Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-005117-31 | Sponsor Protocol Number: W-4282-301 | Start Date*: 2018-10-17 | ||||||||||||||||
Sponsor Name:Wockhardt Bio AG | ||||||||||||||||||
Full Title: A Phase III, Randomized, Double-Blind, Multicenter, Comparative Study to Determine the Efficacy and Safety of Cefepime-Tazobactam vs. Meropenem followed by Optional Oral Therapy in the Treatment of... | ||||||||||||||||||
Medical condition: Complicated urinary tract infection or acute pyelonephritis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: CZ (Temporarily Halted) BG (Temporarily Halted) LV (Completed) LT (Temporarily Halted) PL (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-003772-31 | Sponsor Protocol Number: IT001-302 | Start Date*: 2018-12-07 |
Sponsor Name:Iterum Therapeutics International Limited | ||
Full Title: A prospective, Phase 3, randomized, multi-center, double-blind, double dummy study of the efficacy, tolerability and safety of intravenous sulopenem followed by oral sulopenem-etzadroxil with probe... | ||
Medical condition: Complicated urinary tract infection | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: LV (Completed) HU (Completed) EE (Completed) CZ (Completed) BG (Completed) SK (Completed) HR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2011-005707-32 | Sponsor Protocol Number: MK-7655-003 | Start Date*: 2012-07-13 | ||||||||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | ||||||||||||||||||
Full Title: A Phase II, Randomized, Active Comparator-Controlled Clinical Trial to Study the Safety, Tolerability, and Efficacy of MK-7655 + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone in Patients wit... | ||||||||||||||||||
Medical condition: Patients with Complicated Urinary Tract Infection at least 18 years of age, with a diagnosis of either complicated cUTI or acute pyelonephritis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Prematurely Ended) GR (Completed) LV (Completed) BG (Completed) PL (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2009-015953-18 | Sponsor Protocol Number: DORIPED3002 | Start Date*: 2010-05-28 | |||||||||||
Sponsor Name:Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium | |||||||||||||
Full Title: A Prospective, Randomized, Double-Blind, Multicenter Study to Establish the Safety and Tolerability of Doripenem Compared With Cefepime in Hospitalized Children With Complicated Urinary Tract Infec... | |||||||||||||
Medical condition: Complicated Urinary Tract Infections | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Prematurely Ended) CZ (Completed) PL (Temporarily Halted) LV (Prematurely Ended) DE (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-011466-29 | Sponsor Protocol Number: CXA 101-03 | Start Date*: 2009-06-18 | ||||||||||||||||||||||||||
Sponsor Name:Calixa Therapeutics Inc | ||||||||||||||||||||||||||||
Full Title: A Multicenter, Double-blind, Randomized, Phase 2 Study to Compare the Safety and Efficacy of Intravenous CXA 101 and Intravenous Ceftazidime in Complicated Urinary Tract Infection, Including Pyelon... | ||||||||||||||||||||||||||||
Medical condition: Complicated Urinary tract Infection including Pyelonephritis | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: DE (Completed) PL (Completed) CZ (Prematurely Ended) BE (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-003372-73 | Sponsor Protocol Number: ZTI-01-200 | Start Date*: 2016-04-11 | ||||||||||||||||
Sponsor Name:Zavante Therapeutics, Inc. | ||||||||||||||||||
Full Title: A Multi-center, Randomized, Double-blind, Comparative Study to Evaluate the Safety and Efficacy of ZTI-01 Versus Piperacillin/Tazobactam in the Treatment of Complicated Urinary Tract Infections, In... | ||||||||||||||||||
Medical condition: Complicated Urinary Tract Infections, Including Acute Pyelonephritis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: CZ (Completed) HU (Completed) LT (Completed) LV (Completed) SK (Completed) PL (Completed) EE (Completed) GR (Completed) BG (Completed) RO (Completed) HR (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-000484-28 | Sponsor Protocol Number: LRS114688 | Start Date*: 2011-08-15 | ||||||||||||||||
Sponsor Name:GlaxoSmithKline Research and Development Ltd | ||||||||||||||||||
Full Title: A randomised, double-blind, dose-finding, multicenter study of the safety, tolerability, and efficacy of GSK2251052 therapy compared to imipenem-cilastatin in the treatment of adult subjects with f... | ||||||||||||||||||
Medical condition: Complicated Urinary tract infections (cUTI) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) GR (Prematurely Ended) HU (Completed) ES (Prematurely Ended) IT (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
